Literature DB >> 3037821

Cold-adaptation of human rotavirus.

S Matsuno, S Murakami, M Takagi, M Hayashi, S Inouye, A Hasegawa, K Fukai.   

Abstract

A human rotavirus strain was cold-adapted for possible future use as a live vaccine. The original strain was isolated in 1980 in primary cynomolgus monkey kidney cells and has a serotype I and subgroup II antigenicity. The virus was serially passaged in African green monkey kidney cells; it was cultivated at 37 degrees C at the first stage of passages, and the cultivation temperature was then shifted down stepwise by 3 degrees C per each 10 passages. Finally the virus was passaged 10 times at 25 degrees C (total passage number of 55). The virus formed small-size plaques with irregular shaped borders at 31 degrees C. Growth at 25 degrees C of the cold-adapted virus was higher than that of the original virus. There was no difference between the migration patterns of 11 dsRNA segments in polyacrylamide gel electrophoresis of the original and the cold-adapted viruses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037821     DOI: 10.1016/0168-1702(87)90033-5

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  4 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

Review 2.  Human body temperature and new approaches to constructing temperature-sensitive bacterial vaccines.

Authors:  Matthew D White; Catharine M Bosio; Barry N Duplantis; Francis E Nano
Journal:  Cell Mol Life Sci       Date:  2011-05-31       Impact factor: 9.261

Review 3.  Rotavirus vaccines: an overview.

Authors:  K Midthun; A Z Kapikian
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

4.  Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro.

Authors:  Y Hoshino; A Z Kapikian; R M Chanock
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.